Incidence of Cryptogenic Stroke in Covid-19 Patients

{"title":"Incidence of Cryptogenic Stroke in Covid-19 Patients","authors":"","doi":"10.33140/wjcmi.01.01.012","DOIUrl":null,"url":null,"abstract":"Introduction The risk of ischemic stroke during COVID-19 is approximately 5% reported by WHO. Hemorrhagic strokes are less common compared to ischemic ones, but few cases have been reported. The strokes are called a cryptogenic strokes which means an unknown origin. Diagnostic investigations were incomplete in patients with COVID-19 leading to a high rate of cryptogenic stroke. Materials and Methods It is a prospective observational study conducted at a single centered hospital in Hanamkonda the data was collected from January 2020 to April 2020 and all Parameters were expressed as Mean ± Standard Deviation (SD). Data analysis was performed using MS Excel and Graphpad Prism (9.0 version). A One-Way ANOVA (Analysis of variance) followed by Dunnett’s Multiple Comparison test was done to assess the significant difference between visit 1and visit 3 cryptogenic parameters. A p-value <0.0001 was considered significant. Results There were significant changes observed from visit 1 to visit 3 in evaluating the parameters and treatment of coagulation and inflammation. Conclusion The risk of cryptogenic stroke in COVID-19 infected patients was assessed by considering parameters such as TLC, CRP, LDH, RBS, FERRITIN, D-DIMER, IL-6 and it can be concluded that the evaluation of the above parameters is to be evaluated in every patient irrespective of comorbidities, age, and anti-coagulants, anti-diabeticandanti-inflammatoryagentswillplayasubstantialroleinthe management of cryptogenic stroke in COVID-19.","PeriodicalId":408468,"journal":{"name":"World Journal of Clinical &amp; Medical Images","volume":"53 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Clinical &amp; Medical Images","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/wjcmi.01.01.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction The risk of ischemic stroke during COVID-19 is approximately 5% reported by WHO. Hemorrhagic strokes are less common compared to ischemic ones, but few cases have been reported. The strokes are called a cryptogenic strokes which means an unknown origin. Diagnostic investigations were incomplete in patients with COVID-19 leading to a high rate of cryptogenic stroke. Materials and Methods It is a prospective observational study conducted at a single centered hospital in Hanamkonda the data was collected from January 2020 to April 2020 and all Parameters were expressed as Mean ± Standard Deviation (SD). Data analysis was performed using MS Excel and Graphpad Prism (9.0 version). A One-Way ANOVA (Analysis of variance) followed by Dunnett’s Multiple Comparison test was done to assess the significant difference between visit 1and visit 3 cryptogenic parameters. A p-value <0.0001 was considered significant. Results There were significant changes observed from visit 1 to visit 3 in evaluating the parameters and treatment of coagulation and inflammation. Conclusion The risk of cryptogenic stroke in COVID-19 infected patients was assessed by considering parameters such as TLC, CRP, LDH, RBS, FERRITIN, D-DIMER, IL-6 and it can be concluded that the evaluation of the above parameters is to be evaluated in every patient irrespective of comorbidities, age, and anti-coagulants, anti-diabeticandanti-inflammatoryagentswillplayasubstantialroleinthe management of cryptogenic stroke in COVID-19.
Covid-19患者隐源性卒中的发生率
世卫组织报告,COVID-19期间缺血性中风的风险约为5%。出血性中风较缺血性中风少见,但鲜有报道。这种中风被称为隐源性中风,意思是病因不明。COVID-19患者的诊断调查不完整,导致隐源性卒中发生率高。材料与方法本研究为前瞻性观察性研究,于2020年1月至2020年4月在哈南康田市某单中心医院进行,数据采集时间为2020年1月至2020年4月,所有参数均以均数±标准差(SD)表示。数据分析使用MS Excel和Graphpad Prism(9.0版本)软件。采用单因素方差分析(ANOVA)和邓尼特多重比较检验(Dunnett’s Multiple Comparison test)来评估访问1和访问3的隐基因参数之间的显著性差异。p值<0.0001被认为是显著的。结果从第1次就诊到第3次就诊,凝血和炎症的评价参数和治疗方法发生了显著变化。结论通过TLC、CRP、LDH、RBS、FERRITIN、D-DIMER、IL-6等指标对COVID-19感染患者隐源性卒中的风险进行评估,认为上述指标的评估应在每位患者中进行,而不考虑合并症、年龄,抗凝、抗糖尿病、抗炎药物对COVID-19隐源性卒中的管理具有重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信